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Objective. To analyze the effect of sociodemographic, disease, and health system characteristics and contextual features
about the community of residence on the subsequent initiation of treatment with biologic agents for rheumatoid arthritis
(RA).
Methods. We analyzed data from the University of California, San Francisco Rheumatoid Arthritis Panel Study for the
years 1999–2011. Principal data collection was by a structured annual phone survey. We estimated Kaplan-Meier curves
of the time until initiation of biologic agents, stratiﬁed by age and income. We also used Cox regression to estimate the
effect of individual-level sociodemographic and medical factors, contextual-level socioeconomic status measures, and
density of health providers in the local community on the probability of initiating therapy with biologic agents for RA.
Results. In total, 527 persons were included in the panel in 1999, and 229 persons (44%) had initiated therapy with
biologic agents by 2011. In multivariable Cox regression models, age <70 years (hazard ratio [HR] for ages 19–54 years
1.89 [95% conﬁdence interval (95% CI) 1.24–2.87] and HR for ages 55–69 years 1.25 [95% CI 0.84–1.87]), Hispanic
ethnicity (HR 2.02 [95% CI 1.05–3.86]), household income >$30,000/year (HR 1.61 [95% CI 1.12–2.32]), being married or
with a partner (HR 1.39 [95% CI 1.00–1.92]), and residence in rural environments (HR 1.96 [95% CI 1.28–2.99]) were
associated with a higher probability of initiating biologic agents. Having no (HR 0.18 [95% CI 0.08–0.40]) or only 1–4
rheumatology visits in the year prior to interview (HR 0.60 [95% CI 0.45–0.81]) and living in an area with >1 federally
qualiﬁed health centers (HR 0.63 [95% CI 0.41–0.96]) were associated with a lower probability.
Conclusion. The probability of initiating therapy with biologic agents is affected by sociodemographic and health system
characteristics as well as the nature of the community of residence, resulting in disparities in access to these medications.
INTRODUCTION
Appropriate use of disease-modifying antirheumatic drugs
(DMARDs) has become a cornerstone of care for rheuma-
toid arthritis (RA) (1,2). Despite the universal recommen-
dation for the use of DMARDs in RA, numerous studies
have indicated that these medications are underused (3–
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8). Three studies identiﬁed differences in utilization of
DMARDs by such characteristics as race/ethnicity, socio-
economic status (SES), and type of health plan (5,6,9),
while another study observed that access to these agents,
including biologic agents, was correlated with the wealth
of countries (10). These differences would properly be
regarded as disparities if they could not be attributed to
medical need (11,12).
While the American College of Rheumatology recom-
mends initial treatment of RA with methotrexate or an-
other nonbiologic DMARD prior to therapy with biologic
agents, biologic agents are often warranted because of
incomplete disease control (2). The present study was
designed to analyze whether there are disparities in the
initiation of therapy with biologic agents in a community-
based cohort of persons with RA. The major factors ana-
lyzed included the effect of individual-level sociodemo-
graphic and medical factors (including RA treatments),
contextual-level SES measures, and density of health pro-
viders in the local community on the probability of initi-
ating biologic agents for the treatment of RA.
MATERIALS AND METHODS
Data source. The present study used the University of
California, San Francisco Rheumatoid Arthritis Panel
Study (RAPS). The RAPS began in 1982/1983 by taking a
random sample of half of the rheumatologists then prac-
ticing in Northern California and who, in turn, maintained
a log of all persons with RA presenting over a 1-month
period and veriﬁed the diagnosis. The logs included both
returning and new patients. Subsequent enrollments of
persons with RA using the same sampling method oc-
curred in 1989, 1995, 1999, and 2003 (to maximize the
length of time to estimate time until initiation of the bio-
logic agents, the present analysis was limited to those
enrolled in 1999 or earlier). Overall, 1,447 persons entered
the RAPS during one of the waves of enrollment (85% of
the persons with RA listed on the logs).
The principal data collection for the RAPS is an annual
structured telephone interview conducted by trained sur-
vey workers using validated batteries of items. The survey
collects information on signs and symptoms of RA, the
extent of comorbidity, physical and psychological health
status, functional status, health care utilization informa-
tion, and characteristics of health insurance plans. In the
survey for each year, there is a complete inventory of
all RA treatments received, including medications (name,
duration, and dose). In addition, basic demographic infor-
mation is collected, with updates on items such as marital
and employment status and income, as warranted. Prior
publications provided listings of the speciﬁc validated
batteries included in the surveys (13–15).
Beginning in 1999, the annual RAPS included ques-
tions about usage in the year prior to the interview of
each biologic agent that had been given a Food and Drug
Administration indication for RA. Thus, the surveys from
1999 through 2011 covered usage of biologic agents from
1998 through 2011.
Over the 3 decades of the RAPS data collection, we were
able to reinterview an average of 93% of those interviewed
in the prior year. After excluding deaths, the reinterview
rate averaged 95%. As a result of deaths and attrition, as
of 1999, there were 527 persons enrolled in the RAPS. Data
collection was approved by the University of California,
San Francisco Institutional Review Board.
Statistical analysis. In the present article, we used the
Kaplan-Meier method to estimate time until the ﬁrst initi-
ation of a biologic agent, including any of the following:
etanercept, inﬂiximab, abatacept, adalimumab, anakinra,
and rituximab. We show a Kaplan-Meier curve for the
entire RAPS sample as well as by strata selected on the
basis of characteristics that were shown to be related to
treatment usage in prior studies, including income and
age. In the Kaplan-Meier analyses, censorship of observa-
tions could occur because of death or loss to followup.
Among the 527 persons enrolled in the RAPS, 43% initi-
ated biologic agents, 10% were censored due to death,
15% never initiated biologic agents and were interviewed
through 2011, and 31% were censored because of attrition
at some point. However, even among this latter 31% of
persons, the median number of annual interviews after
1999 was 4.
We then used Cox proportional hazards regression to
estimate the impact of baseline characteristics of individ-
uals and the characteristics of their communities in vari-
ous years, deﬁned at various levels of aggregation, on the
rate of ﬁrst initiation of any biologic agent. The individual
characteristics included these sociodemographic vari-
ables: age (19–54 years, 55–69 years, or 70 years [refer-
ence]); female sex; race (white versus nonwhite); ethnicity
(Hispanic of any race versus non-Hispanic); marital status
(married or with a partner versus other); education attain-
ment (more than high school versus high school graduate
or less); annual household income ($30,000/year versus
$30,000/year); residence area (rural versus urban); insur-
ance status, including whether a health plan was fee-for-
service or some form of managed care and whether the
Signiﬁcance & Innovations
● Introduction of therapy with biologic agents in
rheumatoid arthritis (RA) has dramatically im-
proved outcomes for RA, but differential access to
these agents may create disparities in outcomes.
● Few studies have longitudinal followup of a sufﬁ-
cient duration to study the initiation of therapy
with biologic agents and have a wide range of risk
factors prospectively measured, including charac-
teristics of disease, sociodemographics, health sys-
tems, and local communities.
● The extent of access to rheumatologists and living
in areas with federally qualiﬁed health centers, an
indicator of medical underservice, substantially
reduced the probability of initiating therapy with
biologic agents.
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Table 1. Characteristics of members of the University of California, San Francisco Rheumatoid Arthritis Panel Survey in
1999, by subsequent initiation of biologic agents through 2011*
Total
(n  527)
Started biologic
agents (n  229, 43%)
Never started biologic
agents (n  298, 57%) P
Sociodemographics
Age, mean  SD years 61.2  13.9 56.7  13.3 64.7  13.3 0.00
Women 440 (83) 194 (85) 246 (83) 0.51
Race 0.58
Nonwhite 89 (17) 41 (18) 48 (16)
White 438 (83) 188 (82) 250 (84)
Ethnicity 0.04
Non-Hispanic 490 (93) 207 (90) 285 (95)
Hispanic 37 (7) 22 (10) 15 (5)
Marital status 0.00
Never married/widowed, separated,
or divorced
191 (36) 63 (28) 128 (43)
Married/partner 336 (64) 166 (72) 170 (57)
Education attainment 0.09
High school graduate or less 216 (41) 84 (37) 132 (44)
More than high school 311 (59) 145 (63) 166 (56)
Annual household income 0.00
$30,000/year 190 (38) 56 (26) 134 (48)
$30,000/year 337 (62) 162 (74) 144 (52)
Rural/urban 0.12
Urban 445 (84) 187 (82) 258 (87)
Rural 82 (16) 42 (19) 40 (13)
Insurance status
Managed care 0.67
FFS 94 (18) 39 (17) 55 (18)
HMO/PPO 433 (82) 190 (83) 243 (82)
Pay for drugs 0.01
No 49 (9) 12 (5) 37 (12)
Yes 478 (91) 217 (95) 261 (88)
Visits to rheumatologist 0.00
None 70 (13) 8 (4) 62 (21)
1–4 238 (45) 90 (39) 148 (50)
5 219 (42) 131 (57) 88 (30)
RA-related factors, mean  SD
Disease duration, years 19.6  10.7 18.4  9.8 20.6  11.2 0.02
HAQ score 1.08  0.74 1.01  0.70 1.12  0.77 0.10
No. of swollen joints 2.0  2.7 2.2  2.5 1.8  2.8 0.14
No. of painful joints 4.0  4.5 4.4  4.3 3.7  4.6 0.05
Comorbidities
Geriatric Depression Scale score 7 40 (8) 16 (7) 24 (8) 0.68
No. of comorbidities 0.00
None 279 (53) 140 (61) 139 (47)
1 168 (32) 65 (28) 103 (35)
2 80 (15) 24 (10) 56 (19)
Therapies
Nonbiologic DMARDs 428 (81) 207 (90) 221 (74) 0.00
Oral steroids 273 (52) 133 (58) 140 (47) 0.01
NSAIDs 408 (77) 196 (86) 212 (71) 0.00
Hospitalized in prior 12 months 119 (23) 51 (22) 68 (23) 0.88
Contextual variables
Dartmouth hospital referral regions
Rheumatologists per 100,000 residents 0.84
0.78 382 (72) 167 (73) 215 (72)
0.78 145 (28) 62 (27) 83 (28)
Dartmouth primary care service regions
Federally qualiﬁed health centers 0.53
None 438 (83) 193 (84) 245 (82)
1 89 (17) 36 (16) 53 (18)
American Community Survey block group:
concentrated poverty
0.87
Household incomes at 125% of federal
poverty level
17% 394 (75) 172 (75) 222 (75)
17% 133 (25) 57 (25) 76 (25)
* Values are the number (percentage) unless indicated otherwise. FFS  fee-for-service; HMO/PPO  health maintenance organization/preferred
provider organization; RA  rheumatoid arthritis; HAQ  Health Assessment Questionnaire; DMARDs  disease-modifying antirheumatic drugs;
NSAIDs  nonsteroidal antiinﬂammatory drugs.
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individual had insurance for medications; the number of
visits to a rheumatologist in the year prior to interview
(none, 1–4, or 5 [reference]); RA-related factors, includ-
ing disease duration, number of swollen joints, number of
painful joints, and functional status as measured by the
Health Assessment Questionnaire score; comorbidities as
measured by having a Geriatric Depression Scale score of
7, indicative of major depressive symptomology; the
number of chronic conditions (none, 1, or 2 [reference]);
and therapies other than biologic agents, including oral
steroids, nonbiologic DMARDs, nonsteroidal antiinﬂam-
matory drugs (NSAIDs), and presence of a hospital admis-
sion for RA in the year prior to interview.
The community characteristics included the number of
rheumatologists per 100,000 residents in the hospital re-
ferral region in 2006, as deﬁned by the Dartmouth Atlas of
Health Care, dichotomized as the bottom versus the top 3
quartiles (0.78 per 100,000 residents) (16); whether there
were 1 federally qualiﬁed health centers in the local
area in 2007, an indicator of an area underserved by health
care providers, also as deﬁned by the Dartmouth Atlas of
Health Care; and whether the census block group was an
area with a high concentration of persons with household
incomes 125% of the federal poverty level, as deﬁned by
the American Community Survey for the 5-year period of
2005–2009, dichotomized as the top versus the bottom 3
quartiles (17% of the area’s population having a family
income below the target level) (17). Census block groups
are roughly analogous to a small neighborhood, with ap-
proximately 400–1,000 individuals, and are relatively ho-
mogeneous. We also evaluated the interaction between
living in a community in the lowest quartile of rheuma-
tologists per capita (0.78 per 100,000 residents) and hav-
ing no or few visits to a rheumatologist. This latter analysis
assessed whether the effect of visiting rheumatologists
was contingent on their availability. Finally, we used the
Cox regression estimates to test whether adding commu-
nity characteristics to the full individual-level model re-
sulted in an improvement in model ﬁt, as indicated by the
increase in the chi-square model.
RESULTS
Table 1 shows the characteristics of the RAPS members in
1999, stratiﬁed by whether each initiated biologic agents at
some point between 1998 and 2011. For the entire mem-
bership of the RAPS, the average age was 61 years, more
than four-ﬁfths were women, and 93% were non-Hispanic
white. Approximately 2 in 5 members had household in-
comes $30,000/year. Reﬂecting the age of the mem-
bership, the disease duration averaged 20 years. Health
Assessment Questionnaire scores, averaging 1.08, were in-
dicative of substantial limitation in activities. Approxi-
mately one-half of the RAPS members had taken oral ste-
roids in the year prior to interview, approximately four-
ﬁfths had taken a nonbiologic DMARD, approximately
three-fourths had taken an NSAID, and just under one-
fourth had been hospitalized during this period. Finally,
approximately one-sixth lived in an area with1 federally
qualiﬁed health centers (usually indicative of medically
underserved areas).
As of 2011, 229 RAPS members (44%) had started 1
biologic agents. Those who started biologic agents were
younger and had slightly more involved joints, a dif-
ference that reached statistical signiﬁcance with respect
to painful joints. A greater proportion of those starting
a biologic agent had no comorbid conditions and had
been receiving nonbiologic DMARDs, oral steroids, and
NSAIDs. Of note, those starting a biologic agent were more
likely to report having insurance coverage for prescription
medications (95% versus 88%). A smaller proportion had
a household income of $30,000/year.
In Figure 1A, we show the time until the ﬁrst initiation
of a biologic agent among the RAPS members. Within 2
years of the ﬁrst biologic agents becoming available in
1998, approximately one-ﬁfth of the RAPS members had
initiated biologic agents; by 5 years, approximately one-
third had done so. However, the rate of ﬁrst initiation had
slowed since then; after another 8 years, the proportion
with a ﬁrst initiation of biologic agents had only increased
to 44%.
The proportion initiating biologic agents differed sub-
stantially by income level and age (Figures 1B and C). By
3 years after the ﬁrst biologic agents became available, the
proportion of persons with a household income$30,000/
year who initiated such agents was 10 percentage points
lower than those with higher incomes (approximately 20%
versus 30%); by the end of the period under study (2011),
the proportion of the lower-income group receiving a bio-
logic agent was 20 percentage points lower (30% versus
50%).
The probability of initiating biologic agents decreased
with increasing age. By 2011, 60% of those ages 19–54
years at the outset of the study had initiated a biologic
agent versus40% among those ages 55–69 years and just
slightly more than one-fourth among those ages70 years.
Furthermore, the proportion of the youngest age group
with an initiation of biologic agents continued to increase
substantially until 2006, whereas the proportion of the 2
older age groups with an initiation was essentially stable
after 2004.
Table 2 shows the results of the Cox regression analysis
of the factors affecting time until initiation of biologic
agents. In addition to the 2 factors highlighted in Figure 1
(income level and age), on an unadjusted basis, the prob-
ability of initiating biologic agents was higher among His-
panics (hazard ratio [HR] 1.80 [95% conﬁdence interval
(95% CI) 1.16–2.80]), those who were married or with a
partner (HR 1.69 [95% CI 1.27–2.26]), and persons with
insurance coverage for prescription medications (HR 2.21
[95% CI 1.24–3.95]). On an unadjusted basis, numerous
RA-related and therapeutic factors were associated with
time until initiation of biologic agents, including the num-
ber of swollen and painful joints, level of comorbidity
(with rates of initiation higher among those with no or 1
comorbidity), and receipt of nonbiologic DMARDs, oral
steroids, and NSAIDs. Rates of initiation were higher in
those members with a greater number of visits to rheuma-
tologists in the year prior to the survey. Compared to those
with 5 visits to rheumatologists, those with no (HR 0.13
Factors Inﬂuencing Initiation of Biologic Agents in RA 983
[95% CI 0.06–0.26]) and 1–4 visits (HR 0.50 [95% CI
0.38–0.66]) were much less likely to initiate therapy.
On an unadjusted basis, none of the contextual factors
analyzed (number of rheumatologists per capita, presence
of federally qualiﬁed health centers, and concentration of
poverty in the local area) were associated with the proba-
bility of initiating biologic agents. Because of the strong
effect of the number of rheumatologist visits, we evaluated
whether the effect of such visits was contingent on the
number of rheumatologists per capita in the local area.
However, the interaction term for the conjoint effect of the
number of rheumatologist visits and number of rheuma-
tologists per capita was not signiﬁcantly related to the
initiation of biologic agents, suggesting that the effect of
the extent of contact with rheumatologists on the initiation
of biologic agents was not contingent on the supply of
rheumatologists in the local area.
After adjustment for individual characteristics (Table 2),
younger persons with RA, Hispanics, those with house-
hold incomes $30,000/year, those with a greater number
Figure 1. Kaplan-Meier estimates of time until ﬁrst initiation of a biologic agent
for all Rheumatoid Arthritis Panel Survey members (A) and by income (B) and age
(C). DMARD  disease-modifying antirheumatic drug.
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Table 2. Probability of initiation of biologic agent use through 2011, with and without adjustment for
individual and contextual factors*
Bivariate
models
Multivariable models
Individual
factors
Individual and
contextual factors
Sociodemographics
Age, years
19–54 2.80 (1.97–3.96)† 1.83 (1.20–2.78)† 1.89 (1.24–2.87)†
55–69 1.72 (1.19–2.49) 1.21 (0.81–1.80) 1.25 (0.84–1.87)
70 1 1 1
Sex
Men 1 1 1
Women 1.17 (0.82–1.68) 1.06 (0.72–1.54) 1.04 (0.71–1.53)
Race
Nonwhite 0.88 (0.63–1.23) 1.06 (0.64–1.74) 1.07 (0.65–1.76)
White 1 1 1
Ethnicity
Non-Hispanic 1 1 1
Hispanic 1.80 (1.16–2.80)† 1.98 (1.05–3.72)† 2.02 (1.05–3.86)†
Marital status
Unmarried/divorced 1 1 1
Married/partner 1.69 (1.27–2.26)† 1.35 (0.98–1.87) 1.39 (1.00–1.92)†
Education attainment
High school graduate or less 1 1 1
More than high school 1.27 (0.97–1.66) 1.14 (0.85–1.52) 1.15 (0.86–1.54)
Annual household income
$30,000/year 1 1 1
$30,000/year 2.01 (1.49–2.72)† 1.67 (1.16–2.39)† 1.61 (1.12–2.32)†
Rural/urban
Urban 1 1 1
Rural 1.39 (1.00–1.94) 1.54 (1.08–2.20)† 1.96 (1.28–2.99)†
Insurance status
Managed care
FFS 1 1 1
HMO/PPO 1.02 (0.72–1.44) 0.69 (0.47–1.02) 0.68 (0.46–1.00)
Pay for drugs
No 1 1 1
Yes 2.21 (1.24–3.95)† 1.16 (0.63–2.14) 1.17 (0.63–2.16)
Visits to rheumatologist
None 0.13 (0.06–0.26)† 0.19 (0.09–0.41)† 0.18 (0.08–0.40)†
1–4 0.50 (0.38–0.66)† 0.62 (0.46–0.82)† 0.60 (0.45–0.81)†
5 1 1 1
RA-related factors
Disease duration, years
25 1 1 1
25 0.97 (0.72–1.30) 1.26 (0.92–1.73) 1.23 (0.89–1.69)
HAQ score
1.6 1 1 1
1.6 0.94 (0.70–1.25) 1.09 (0.78–1.52) 1.09 (0.78–1.52)
No. of swollen joints
3 1 1 1
3 1.45 (1.11–1.91)† 1.34 (0.98–1.84) 1.36 (0.99–1.86)
No. of painful joints
6 1 1 1
6 1.37 (1.04–1.80)† 1.22 (0.89–1.69) 1.21 (0.87–1.66)
Comorbidities
Geriatric Depression Scale score
7 1 1 1
7 0.94 (0.57–1.56) 1.16 (0.67–2.01) 1.16 (0.66–2.02)
No. of comorbidities
None 1.87 (1.21–2.88)† 1.69 (1.04–2.75)† 1.72 (1.06–2.80)†
1 1.37 (0.86–2.18) 1.41 (0.86–2.30) 1.44 (0.88–2.36)
2 1 1 1
(continued)
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of visits to rheumatologists, and those taking NSAIDs re-
mained more likely to initiate biologic agents. However,
the effects of marital status, medication coverage, level of
involved joints, extent of comorbidity, and receipt of non-
biologic DMARDs and oral steroids were no longer signif-
icant, while living in a rural area (HR 1.54 [95% CI 1.08–
2.20]) was associated with a higher rate of initiation. After
further adjustment for contextual factors (Table 2), among
the contextual factors, only the presence of a federally
qualiﬁed health center was associated with the initiation
of biologic agents (HR 0.63 [95% CI 0.41–0.96]), indicating
that those living in an area with such a center were much
less likely to initiate therapy. However, when we evalu-
ated whether the addition of the contextual variables as a
group provided an increment of explanatory power by
comparing the chi-square model from the restricted and
expanded models, the results indicated that the addition
did not signiﬁcantly improve the ﬁt (P  0.11).
DISCUSSION
Among all therapies for RA, biologic agents present the
greatest challenge for the goal of achieving equitable ac-
cess to effective treatment and reducing disparities in out-
comes. The cost of these agents, especially the out-of-
pocket share borne by persons with RA, is the most
tangible aspect of the challenge. However, there are other
aspects, including differential access to rheumatologists
who have the most familiarity with biologic agents and
receiving care in health systems that have more restrictive
treatment protocols, such as requiring multiple failed reg-
Table 2. (Cont’d)
Bivariate
models
Multivariable models
Individual
factors
Individual and
contextual factors
Therapies
Nonbiologic DMARDs
No 1 1 1
Yes 2.62 (1.68–4.06)† 1.27 (0.78–2.05) 1.29 (0.79–2.10)
Oral steroids
No 1 1 1
Yes 1.46 (1.13–1.90)† 1.06 (0.79–1.42) 1.01 (0.75–1.36)
NSAIDs
No 1 1 1
Yes 2.01 (1.39–2.91)† 1.50 (1.02–2.21)† 1.50 (1.02–2.20)†
Hospitalized in prior 12 months
No 1 1 1
Yes 1.04 (0.76–1.41) 1.04 (0.75–1.45) 1.03 (0.74–1.43)
Contextual variables
Dartmouth hospital referral regions
Rheumatologists per 100,000 residents
0.78 1 1
0.78 1.00 (0.75–1.34) 1.07 (0.77–1.47)
Dartmouth primary care service regions
Federally qualiﬁed health centers
None 1 1
1 0.93 (0.70–1.25) 0.63 (0.41–0.96)†
American Community Survey block group
Household incomes at 125% of federal
poverty level
17% 1 1
17% 1.00 (0.74–1.35) 0.83 (0.20–3.41)
Interaction of individual and contextual variables
No. of visits to rheumatologist/supply of
rheumatologists
None/low 0.19 (0.08–0.46)
1–4/low 0.56 (0.36–0.89)
5/low 1.02 (0.69–1.52)
None/high 0.08 (0.03–0.26)
1–4/high 0.49 (0.36–0.67)
5/high 1
* Values are the hazard ratio (95% conﬁdence interval). FFS  fee-for-service; HMO/PPO  health maintenance organization/
preferred provider organization; RA  rheumatoid arthritis; HAQ  Health Assessment Questionnaire; DMARDs  disease-
modifying antirheumatic drugs; NSAIDs  nonsteroidal antiinﬂammatory drugs.
† Signiﬁcant.
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imens with nonbiologic DMARDs rather than 1 or 2 before
permission to prescribe a biologic agent is granted.
There are legitimate issues about the extent to which
persons with RA should have biologic agents included in
their regimen, especially in the absence of an adequate
trial of methotrexate or another nonbiologic DMARD or a
speciﬁc contraindication to the continued use of such
agents. Nevertheless, there is strong evidence supporting
the use of biologic agents either alone (18) or in combina-
tion with nonbiologic DMARDs (19) once 1 of these
criteria have been met. Given this evidence, and no coun-
ter evidence that biologic agents are less effective in spe-
ciﬁc sociodemographic subgroups, it is a matter of equity
that usage rates of these agents should be determined by
medical need and patient preferences rather than by such
characteristics as race/ethnicity, SES, the type of health
system in which care is received, or the nature of the
community in which one resides.
The present study took advantage of a longitudinal co-
hort study of persons with RA originally sampled from a
random group of Northern California rheumatologists to
track the usage of biologic agents after the ﬁrst biologic
agents were approved in 1998 and to compare the time
until ﬁrst initiation of biologic agents as a function of
medical and sociodemographic characteristics of persons
with RA, as well as characteristics of their health systems
and local communities. Because many of the persons with
RA had migrated away from the rheumatologist practices
that initially enrolled them, but many had not, we were
able to measure the impact of the extent of contact with
rheumatologists on the time to initiation of a biologic
agent.
In this sample of persons who had had RA for just under
2 decades on average when biologic agents ﬁrst became
available, 44% had initiated biologic agents by the end of
the study. The rate of initiation was much greater initially;
one-third of the RAPS members had initiated biologic
agents in the ﬁrst 5 years, but the proportion only increased
another 10 percentage points after 8 more years. Consistent
with the study by Chu et al (9), we observed an increased
probability of initiation among Hispanics; however, we
also observed some substantial disparities in the expected
direction. We observed lower rates of initiation among
persons with RA with household incomes of $30,000/
year, among those living alone, among those 70 years of
age, and among those living in areas with federally quali-
ﬁed health centers, an indication of medically under-
served areas. In addition, the probability of initiation was
substantially lower among those with no visits and those
with relatively few visits to rheumatologists than among
those with 5 visits. Although the latter ﬁnding was not
altered by adjustment for RA-related factors, it still may
reﬂect in part unmeasured differences in the severity of
disease. To the extent that it does not merely reﬂect such
differences, this ﬁnding indicates that access to rheuma-
tologists is a crucial pathway to the initiation of biologic
agents. This echoes prior studies of access to DMARDs for
RA (3,6,8).
The observation that the probability of initiating bio-
logic agents was lower among those living in areas with
federally qualiﬁed health centers may indicate that such
areas may have fewer medical care resources available to
access as a result of the poverty of many of the residents in
these areas. Alternatively, this observation may indicate
that physicians practicing in such centers may not be able
to secure access to specialty care by rheumatologists be-
cause of a lack of insurance or, among the insured, the
limits faced by those with Medicaid (20), which may ex-
acerbate the normal difﬁculties primary care physicians
face in gaining access to specialists for their patients (21).
Many health insurance programs in the US limit total
out-of-pocket expenses; some, like Medicare, have sepa-
rate limits for medications and other expenses. Few
health insurance plans, however, scale the amount of the
limit to incomes. Thus, although after adjustment we
were able to observe only small differences in the proba-
bility of initiation of biologic agents that did not reach
statistical signiﬁcance by whether or not the person with
RA reported having medication coverage (HR 1.17 [95% CI
0.63–2.16]), the effect of having a household income
$30,000/year was much larger (HR 1.61 [95% CI 1.12–
2.32]) and did reach statistical signiﬁcance. The effect of
out-of-pocket payments would appear to be more pro-
found for biologic agents in RA than other diseases, per-
haps because of the option of continuing therapy using
only nonbiologic DMARDs and because persons with RA
have been shown to be more sensitive to the magnitude
of out-of-pocket payments for biologic agents than persons
with such conditions as cancer, kidney disease, and mul-
tiple sclerosis (22).
This is not the ﬁrst study to observe age-related differ-
ences in RA treatment. Schmajuk and colleagues (5) ob-
served that, even among Medicare managed care beneﬁ-
ciaries, those ages85 years had rates of DMARD usage 30
percentage points lower than those between 65 and 69
years of age. The results of our study of the time until
initiation of biologic agents and the study by Schmajuk
and colleagues suggest that, even when coverage is appar-
ently adequate or even equivalent, there may be different
expectations for the expected beneﬁt for older patients
on the part of physicians, or the expected out-of-pocket
payments may be too large of a burden for those of older
ages, perhaps because of the depletion of their savings over
time. Older patients may also differ in their preferences for
speciﬁc treatments.
Our observation of higher rates of initiation of biologic
agents among Hispanics and no difference in rates by race
suggests that, at least in this well-insured population, ac-
cess to biologic agents was at least as great among members
of minority groups as the general RAPS population, and
that usage may be determined more by income and other
demographic characteristics, such as age, than race. The
results of our study may not be generalizable to the entire
population of persons with RA in the US; the study sample
had had their disease for a long time, the proportion of
minorities was relatively small, all persons had been to a
rheumatologist at some point, and all persons had some
insurance coverage. Furthermore, managed care has a high
share of the health insurance market in Northern Califor-
nia; even by the outset of the study in 1999, 82% of the
cohort was enrolled in managed care health plans. How-
ever, some of these characteristics, particularly the long
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disease duration, high rates of nonbiologic DMARD usage,
and history of interaction with rheumatologists at some
point, may have made the results a conservative assess-
ment of the impact of sociodemographic and health system
characteristics and contextual factors on time until initia-
tion of biologic agents. For example, one would expect that
disparities by age or income would be muted in well-
insured populations. Another limitation is that age- and
income-related disparities in usage may have been due to
differences in contraindications to or preferences for treat-
ment, neither of which were directly measured in the
RAPS annual survey.
The introduction of biologic agents has had a profound
effect on outcomes for RA, especially for those who have
failed 1 nonbiologic DMARDs. In this study, we ob-
served that those with lower incomes, older persons, and
those who were not married or living with a partner expe-
rienced a longer time until initiation of biologic agents.
Those with no as opposed to some or more frequent con-
tact with rheumatologists also experienced a longer time
until initiation of treatment with biologic agents. The ef-
fect of income, age, and marital status remained signiﬁcant
after controlling for the frequency of contact with rheu-
matologists, indicating that the effect of these sociodemo-
graphic characteristics was not due to differential access
to rheumatologist care. There may be different reasons
for each of these disparities. Individuals in low-income
households may choose not to pursue treatment with bio-
logic agents because of the out-of-pocket costs. Perhaps
there was an element of age discrimination in the substan-
tially lower rates of usage among persons ages 70 years,
or a higher rate of clinical contraindications, such as a
history of tuberculosis infection. Those who were married
or with a partner may have had the beneﬁt of being per-
suaded to initiate such therapy despite its costs.
Time until initiation of biologic agents was substantially
lengthened for those who had low income, those who were
older, and those who were living alone, indicating dispar-
ities in access to these agents that have been shown to be
effective in treating RA. Clinicians must be cognizant that
their ability to communicate with persons from these
backgrounds does not result in these disparities (23). To
reduce the chance of this happening, they might proﬁtably
initiate the use of decision aid tools designed to inform
persons with RA about treatment options (24), especially
when such persons are from vulnerable groups, including
the poor and elderly.
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